



ASX release

28 January 2009

**US \$0.860m new pharmaceutical & biotech trial contracts
Over US \$6.5m new contracts in past 8 months**

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has signed new agreements to supply SphygmoCor[®] systems and clinical trial support services to a US biotech company and a leading international pharmaceutical company. The minimum total value of the contracts is US \$650,000 and US \$210,000 respectively. These new orders bring the minimum total value of pharmaceutical trial contracts secured by AtCor in the past eight months to over US \$6.5 million.

Duncan Ross, CEO of AtCor Medical, said: "We continue to execute on our strategy, which is producing strong growth despite a tough macro-economic environment. These new contracts show the increasing importance of SphygmoCor[®] as a tool for understanding drug efficacy and mechanisms of action in pharmaceutical and biotechnology clinical trials, as well as SphygmoCor's significance as a drug therapy management tool in clinical practice. We look forward to continuing to build mutually beneficial relationships with our expanding list of clinical trial customers."

Mr. Ross added, "The growing use of SphygmoCor[®] systems in clinical trials and the increasing volume of publications concerning central blood pressures and arterial stiffness continue the push toward establishment of a new standard for cardiovascular risk assessment and management."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor[®] system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,800 SphygmoCor[®] systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies, and the company's technology have been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au

SphygmoCor[®] is a registered trademark of AtCor Medical Pty Ltd and its related entities.